After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

The worst appears to be over for Mylan NV and its EpiPen controversy. It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive ...

Mylan, which showered itself in infamy by jacking up the price of its EpiPen, a potentially life-saving epinephrine injector, by 500% over less than a decade, announced Friday that it is finally ...

Tax experts have said that Mylan is actually paying much less in taxes. Excluding taxes, EpiPen’s profits per two-pack are close to $170. This left lawmakers shaking their heads. “We didn’t ...

Mylan investors sent shares reeling after the generics giant reported poor first-quarter numbers. | To hear some analysts tell it, Mylan executives aren't performing up to par, and some behind-the ...

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.